Searchable abstracts of presentations at key conferences in endocrinology

ea0041oc5.3 | Neuroendocrinology | ECE2016

Development of a long-acting growth hormone antagonist for the treatment of acromegaly

Wilkinson Ian , Pradhananga Sarbendra , Speak Rowena , Sayers Jon , Ross Richard

Background: The UK acromegaly register reported that <60% of acromegalics on medical therapy had controlled disease (1). Pegvisomant, a growth hormone antagonist (GHA), controls disease in >95% cases, but is not cost-effective and requires high dose daily injections (2). We have developed a fusion technology for making a cost-effective long-acting GH molecule (3), and generated a GHA by linking mutated growth hormone to its binding protein (GHBP).<p class="abstext"...

ea0038oc2.4 | Translational pathophysiology and therapeutics | SFEBES2015

Development of a long-acting growth hormone antagonist for the treatment of acromegaly

Speak Rowena , Pradhananga Sarbendra , Justice Sue , Ross Richard , Wilkinson Ian

Background: The UK acromegaly register reported that <60% of acromegalics on medical therapy had controlled disease (1). This is because many patients do not respond to somatostatin therapy. Pegvisomant, a growth hormone antagonist (GHA), controls disease in >95% cases, but is not cost-effective and requires high dose daily injections (2). There is therefore an unmet need for a cost-effective GHA. We have developed a fusion technology for making a cost-effective long-a...

ea0063oc3.2 | Cushing's and acromegaly | ECE2019

Outcomes after primary treatment for Nelson’s syndrome: a study from 13 UK centres

Fountas Athanasios , Lim Eugenie , Drake William M , Polson Andrew , Gurnell Mark , Martin Niamh M , Seejore Khyatisha , Murray Robert D , MacFarlane James , Ahluwalia Rupa , Swords Francesca , Ashraf Muhammad , Pal Aparna , Chong Zhuomin , Freel Marie , Balafshan Tala , Purewal Tejpal S , Speak Rowena G , Newell-Price John , Higham Claire , Hussein Ziad , Baldeweg Stephanie E , Dales Jolyon , Reddy Narendra , Levy Miles , Karavitaki Niki

NelsonÂ’s syndrome (NS) is a potentially severe complication following bilateral adrenalectomy for CushingÂ’s disease (CD). Series assessing outcomes of treatments for NS are limited by small sample size, often short follow-up and variability of success criteria. We performed a UK multi-centre study aiming to review outcomes of primary treatment for NS. Clinical, laboratory, imaging data were collected. Kaplan-Meier method, log-rank test, Cox regression analysis were u...